TSE:4528Pharmaceuticals
How Investors Are Reacting To Ono Pharmaceutical (TSE:4528) Winning Japanese Approval for New Braftovi Cancer Therapy
Ono Pharmaceutical recently received supplemental approval in Japan for Braftovi (encorafenib) capsule in combination with cetuximab and chemotherapy for treating unresectable, advanced, or recurrent colorectal cancer with BRAF mutation, following positive Phase III trial results.
This milestone reflects Ono's ongoing progress in advancing new cancer therapies, supported by rigorous global clinical study data and regulatory recognition.
We'll explore how regulatory progress in oncology,...